In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles - CNRS - Centre national de la recherche scientifique Accéder directement au contenu
Article Dans Une Revue Nanomedicine Année : 2023

In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles

Hugo Rositi
Cyrille Monnereau
Andreas Ko Åslund
Sofie Nyström
Per Hammarström

Résumé

Aim: To propose a new multimodal imaging agent targeting amyloid-β (Aβ) plaques in Alzheimer’s disease. Materials & methods: A new generation of hybrid contrast agents, based on gadolinium fluoride nanoparticles grafted with a pentameric luminescent-conjugated polythiophene, was designed, extensively characterized and evaluated in animal models of Alzheimer’s disease through MRI, two-photon microscopy and synchrotron x-ray phase-contrast imaging. Results & conclusion: Two different grafting densities of luminescent-conjugated polythiophene were achieved while preserving colloidal stability and fluorescent properties, and without affecting biodistribution. In vivo brain uptake was dependent on the blood–brain barrier status. Nevertheless, multimodal imaging showed successful Aβ targeting in both transgenic mice and Aβ fibril-injected rats.
Fichier principal
Vignette du fichier
nnm-2022-0252.pdf (8.01 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04038718 , version 1 (21-03-2023)

Identifiants

Citer

Frédéric Lerouge, Elodie Ong, Hugo Rositi, Francis Mpambani, Lise-Prune Berner, et al.. In vivo targeting and multimodal imaging of cerebral amyloid-β aggregates using hybrid GdF 3 nanoparticles. Nanomedicine, 2023, 17 (29), pp.2173-2187. ⟨10.2217/nnm-2022-0252⟩. ⟨hal-04038718⟩
47 Consultations
87 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More